drugset / Trial / NCT04373785
NG101m Adjuvant Therapy in Glioblastoma Patients
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this clinical trial is to evaluate the addition of NG101m adjuvant therapy to standard of care treatment of glioblastoma multiforme. All subjects will receive NG101m capsules along with the standard treatment of temozolomide and radiation.
Timeline
- Start
- 2027-01-01
- Primary completion
- 2030-07-30
- Completion
- 2030-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | NG101m | Unknown | — | Oral |
| Background | Temozolomide | Small molecule | 150 mg/m2 | Oral |
| Background | Temozolomide | Small molecule | 200 mg/m2 | Oral |